C2N Diagnostics

New Capabilities

As of August 2026: FDA cleared PrecivityAD2 for adults 40 and older (August 2026)

Alzheimer's diagnosis used to require a $5,000 brain scan or a painful spinal tap. As of August 2026, the FDA has cleared four blood tests for the disease, from Roche's Elecsys pTau217 to C2N's PrecivityAD2, approved for adults as young as 40.

Updated Aug 25